Tetrapeptide selective μ1-opioid receptor agonists – the missing link in the treatment of chronic pain in oncology?
Year: 2026
Type: article
Abstract: Chronic pain syndrome remains one of the major unresolved problems in oncology: some patients continue to experience breakthrough pain, insufficient response to therapy, opioid-related adverse effects, reduced treatment adherence, tolerance, and opioid phobia. In this context, new analgesics with high efficacy and a more favorable safety profile are of particular interest. Taphalgin, a domestic tetrapeptide selective μ1-opioid receptor agonist, differs from classical opioids by lacking interaction with μ2-receptors, which may reduce the risk of adverse effects such as respiratory depression, impaired gastrointestinal motility, euphoria, and miosis. In phase II and III clinical trials, as well as in individual clinical observations, the drug demonstrated a pronounced analgesic effect in chronic cancer pain, comparable to that of morphine, with a lower incidence of adverse events and the possibility of long-term use without signs of significant tolerance or dependence. Selective peptide opioid receptor agonists may be regarded as a promising direction in the treatment of chronic pain in oncology, especially in cases of intolerance, insufficient efficacy, or limitations associated with the use of traditional opioid analgesics. Aim. To analyze the challenges in managing chronic pain syndrome in cancer patients and to evaluate the prospects of using selective tetrapeptide agonists of μ1-opioid receptors, using tafalgin as an example, taking into account its pharmacological features, clinical trial results, and real-world clinical practice experience.
Source: Head and neck tumors (HNT)
Author: A. A. Ivanov
Language: English
Subfield: Anesthesiology and Pain Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7236707083
